3.4 USD
-0.09 (-2.58%)
We assign a fundamental rating of 3 out of 10 to CCEL. CCEL was compared to 101 industry peers in the Health Care Providers & Services industry. While CCEL is still in line with the averages on profitability rating, there are concerns on its financial health. CCEL does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
CCEL had negative earnings in the past year.
CCEL had a positive operating cash flow in the past year.
Of the past 5 years CCEL 4 years were profitable.
CCEL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
CCEL has a Return On Assets of -0.75%. This is comparable to the rest of the industry: CCEL outperforms 45.54% of its industry peers.
With a decent Return On Invested Capital value of 7.64%, CCEL is doing good in the industry, outperforming 71.29% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for CCEL is in line with the industry average of 9.58%.
The 3 year average ROIC (7.61%) for CCEL is below the current ROIC(7.64%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.75% | ||
| ROE | N/A | ||
| ROIC | 7.64% |
ROA(3y)-3.55%
ROA(5y)0.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.61%
ROIC(5y)11.38%
1.3 Margins
CCEL's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 13.63%, CCEL belongs to the top of the industry, outperforming 84.16% of the companies in the same industry.
In the last couple of years the Operating Margin of CCEL has declined.
Looking at the Gross Margin, with a value of 77.07%, CCEL belongs to the top of the industry, outperforming 91.09% of the companies in the same industry.
In the last couple of years the Gross Margin of CCEL has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.63% | ||
| PM (TTM) | N/A | ||
| GM | 77.07% |
OM growth 3Y-12.93%
OM growth 5Y-12.62%
PM growth 3Y-44.14%
PM growth 5Y-29.46%
GM growth 3Y2.95%
GM growth 5Y1.88%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CCEL is destroying value.
CCEL has less shares outstanding than it did 1 year ago.
CCEL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CCEL has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.05, we must say that CCEL is in the distress zone and has some risk of bankruptcy.
CCEL has a worse Altman-Z score (0.05) than 80.20% of its industry peers.
The Debt to FCF ratio of CCEL is 1.36, which is an excellent value as it means it would take CCEL, only 1.36 years of fcf income to pay off all of its debts.
CCEL has a better Debt to FCF ratio (1.36) than 87.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 1.36 | ||
| Altman-Z | 0.05 |
ROIC/WACC0.63
WACC12.06%
2.3 Liquidity
CCEL has a Current Ratio of 0.63. This is a bad value and indicates that CCEL is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.63, CCEL is doing worse than 86.14% of the companies in the same industry.
CCEL has a Quick Ratio of 0.63. This is a bad value and indicates that CCEL is not financially healthy enough and could expect problems in meeting its short term obligations.
CCEL's Quick ratio of 0.60 is on the low side compared to the rest of the industry. CCEL is outperformed by 83.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.63 | ||
| Quick Ratio | 0.6 |
3. Growth
3.1 Past
CCEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.34%, which is quite impressive.
The earnings per share for CCEL have been decreasing by -29.04% on average. This is quite bad
Looking at the last year, CCEL shows a decrease in Revenue. The Revenue has decreased by -0.29% in the last year.
CCEL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.11% yearly.
EPS 1Y (TTM)94.34%
EPS 3Y-41.85%
EPS 5Y-29.04%
EPS Q2Q%-30.77%
Revenue 1Y (TTM)-0.29%
Revenue growth 3Y3.46%
Revenue growth 5Y0.11%
Sales Q2Q%-2.99%
3.2 Future
The Earnings Per Share is expected to decrease by -202.32% on average over the next years. This is quite bad
The Revenue is expected to decrease by -3.22% on average over the next years.
EPS Next Y87%
EPS Next 2Y-202.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-1.55%
Revenue Next 2Y-3.22%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CCEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CCEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CCEL indicates a rather cheap valuation: CCEL is cheaper than 91.09% of the companies listed in the same industry.
97.03% of the companies in the same industry are more expensive than CCEL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.43 | ||
| EV/EBITDA | 5.7 |
4.3 Compensation for Growth
CCEL's earnings are expected to decrease with -202.32% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-202.32%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CCEL has a Yearly Dividend Yield of 25.13%, which is a nice return.
The stock price of CCEL dropped by -25.11% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
CCEL's Dividend Yield is rather good when compared to the industry average which is at 0.60. CCEL pays more dividend than 100.00% of the companies in the same industry.
CCEL's Dividend Yield is rather good when compared to the S&P500 average which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 25.13% |
5.2 History
CCEL has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
CCEL has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-1109.12%
EPS Next 2Y-202.32%
EPS Next 3YN/A
NYSEARCA:CCEL (12/30/2025, 8:10:03 PM)
3.4
-0.09 (-2.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners7.19%
Inst Owner Change-0.69%
Ins Owners41.98%
Ins Owner Change2.25%
Market Cap27.40M
Revenue(TTM)31.75M
Net Income(TTM)-473.50K
Analysts43.33
Price Target8.67 (155%)
Short Float %0.17%
Short Ratio1.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 25.13% |
Yearly Dividend0.25
Dividend Growth(5Y)N/A
DP-1109.12%
Div Incr Years1
Div Non Decr Years1
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)227.45%
Min EPS beat(2)178.43%
Max EPS beat(2)276.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.61%
Min Revenue beat(2)-3.88%
Max Revenue beat(2)-3.33%
Revenue beat(4)0
Avg Revenue beat(4)-2.41%
Min Revenue beat(4)-3.88%
Max Revenue beat(4)-0.9%
Revenue beat(8)0
Avg Revenue beat(8)-2.16%
Revenue beat(12)2
Avg Revenue beat(12)-0.97%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-125%
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.86 | ||
| P/FCF | 4.43 | ||
| P/OCF | 4.31 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.7 |
EPS(TTM)-0.06
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)0.77
FCFY22.56%
OCF(TTM)0.79
OCFY23.19%
SpS3.94
BVpS-1.84
TBVpS-2.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.75% | ||
| ROE | N/A | ||
| ROCE | 9.68% | ||
| ROIC | 7.64% | ||
| ROICexc | 8.24% | ||
| ROICexgc | 8.84% | ||
| OM | 13.63% | ||
| PM (TTM) | N/A | ||
| GM | 77.07% | ||
| FCFM | 19.48% |
ROA(3y)-3.55%
ROA(5y)0.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.61%
ROIC(5y)11.38%
ROICexc(3y)7.98%
ROICexc(5y)14.72%
ROICexgc(3y)8.63%
ROICexgc(5y)16.85%
ROCE(3y)9.64%
ROCE(5y)14.41%
ROICexgc growth 3Y-17.95%
ROICexgc growth 5Y-25.17%
ROICexc growth 3Y-16.74%
ROICexc growth 5Y-23.68%
OM growth 3Y-12.93%
OM growth 5Y-12.62%
PM growth 3Y-44.14%
PM growth 5Y-29.46%
GM growth 3Y2.95%
GM growth 5Y1.88%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 1.36 | ||
| Debt/EBITDA | 1.54 | ||
| Cap/Depr | 17.31% | ||
| Cap/Sales | 0.54% | ||
| Interest Coverage | 2.13 | ||
| Cash Conversion | 119.5% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.63 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z | 0.05 |
F-Score7
WACC12.06%
ROIC/WACC0.63
Cap/Depr(3y)548.95%
Cap/Depr(5y)370.25%
Cap/Sales(3y)23.15%
Cap/Sales(5y)15.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.34%
EPS 3Y-41.85%
EPS 5Y-29.04%
EPS Q2Q%-30.77%
EPS Next Y87%
EPS Next 2Y-202.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.29%
Revenue growth 3Y3.46%
Revenue growth 5Y0.11%
Sales Q2Q%-2.99%
Revenue Next Year-1.55%
Revenue Next 2Y-3.22%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.52%
EBIT growth 3Y-9.92%
EBIT growth 5Y-12.52%
EBIT Next Year43.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y112.76%
FCF growth 3Y-15.98%
FCF growth 5Y-8.62%
OCF growth 1Y-20.62%
OCF growth 3Y-8.81%
OCF growth 5Y-1.01%
CRYO-CELL INTL INC / CCEL FAQ
What is the fundamental rating for CCEL stock?
ChartMill assigns a fundamental rating of 3 / 10 to CCEL.
Can you provide the valuation status for CRYO-CELL INTL INC?
ChartMill assigns a valuation rating of 2 / 10 to CRYO-CELL INTL INC (CCEL). This can be considered as Overvalued.
Can you provide the profitability details for CRYO-CELL INTL INC?
CRYO-CELL INTL INC (CCEL) has a profitability rating of 5 / 10.
What is the financial health of CRYO-CELL INTL INC (CCEL) stock?
The financial health rating of CRYO-CELL INTL INC (CCEL) is 3 / 10.